Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 11/20 | 0.41 |
| ▸ | GSK3B | P49841 | 9/20 | 0.41 |
| ▸ | GPR39 | O43194 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4185251 | 0.81 | GPR39 (0.44) | DYRK1AGSK3BGPR39GRM5AXL | |
| SCHEMBL3661666 | 0.79 | GPR39 (0.45) | GPR39GRM5AXLTYRO3MERTK | |
| SCHEMBL3720880 | 0.75 | GPR39 (0.38) | DYRK1AGSK3BGPR39GRM5TYRO3 | |
| SCHEMBL3665002 | 0.74 | GPR39 (0.47) | GPR39AXLTYRO3MERTKEGFR | |
| SCHEMBL4175691 | 0.72 | CYP1A2 (0.46) | GPR39GRM5ALDH1A1HSD17B10 | |
| SCHEMBL3664859 | 0.70 | GPR39 (0.51) | GSK3BGPR39KDM4EALDH1A1AXL | |
| SCHEMBL3663909 | 0.70 | GPR39 (0.54) | GSK3BGPR39KDM4EALDH1A1AXL | |
| SCHEMBL3728645 | 0.70 | CYP11B1 (0.42) | DYRK1AGSK3BGPR39GRM5KDM4E | |
| SCHEMBL3663705 | 0.70 | GPR39 (0.43) | DYRK1AGSK3BGPR39AXLTYRO3 | |
| SCHEMBL4192009 | 0.70 | GPR39 (0.43) | DYRK1AGPR39AXLTYRO3MERTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2242742-B1 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| US-8343966-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-01-01 | — | — | US | disclosed |
| EP-2242742-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090215776-A1 | Organic compounds | ADCOCK CLAIRE | 2009-08-27 | — | — | US | disclosed |
| WO-2009087212-A2 | PYRIDINE DERIVATIVES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215776-A1 | Organic compounds | REN, RXFP1, MYLK | DYRK1A 4748/4885GSK3B 3011/4885GPR39 222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.